Histopathological changes and clinical responses of buruli ulcer plaque lesions during chemotherapy: A role for surgical removal of necrotic tissue?

PLoS Neglected Tropical Diseases

Volumn 5, Issue 9, 2011, Pages

  Ruf, Marie Thérèse ^a,b   Sopoh, Ghislain Emmanuel ^c   Brun, Luc Valère ^d   Dossou, Ange Dodji ^c   Barogui, Yves Thierry ^e   Johnson, Roch Christian ^f   Pluschke, Gerd ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Centre de Depistage et de Traitement de l Ulcer de Buruli d Allada   (Benin)

^d Benin   (Benin)

^e Centre de Depistage et de Traitement de l'Ulcere de Buruli de Lalo   (Benin)

^f Fondation Raoul Follereau ^*  (Benin)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ACID FAST BACTERIUM; ARTICLE; BURULI ULCER; CELL INFILTRATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEBRIDEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PUNCH BIOPSY; SCHOOL CHILD; SKIN TRANSPLANTATION; SUBCUTANEOUS TISSUE; T LYMPHOCYTE; TISSUE NECROSIS; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; BENIN; BIOPSY; CYTOCHEMISTRY; DRUG THERAPY; FEMALE; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROSCOPY; MIDDLE AGED; MYCOBACTERIUM ULCERANS; PATHOLOGY; PRESCHOOL CHILD; SKIN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BENIN; BIOPSY; BURULI ULCER; CHILD; CHILD, PRESCHOOL; DEBRIDEMENT; DRUG THERAPY; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MIDDLE AGED; MYCOBACTERIUM ULCERANS; RIFAMPIN; SKIN; STREPTOMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053439967     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001334     Document Type: Article

References (24)

1. Asiedu K, Scherpbier R, Raviglione M, (2000) Buruli ulcer: Mycobacterium ulcerans infection. Geneva World Health Organization.
2. Buruli ulcer (2000) Wkly. Epidemiol Rec 75: 106-108.
3. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, et al. (2005) Mycobacterium ulcerans disease. Bull World Health Organ 83: 785-791 doi:/S0042-96862005001000016.
4. Thangaraj HS, Evans MR, Wansbrough-Jones MH, (1999) Mycobacterium ulcerans disease; Buruli ulcer. Trans R Soc Trop Med Hyg 93: 337-340.
5. Johnson PDR, Stinear T, Small PLC, Pluschke G, Merritt RW, et al. (2005) Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2: e108 doi:10.1371/journal.pmed.0020108.
6. Buruli ulcer: progress report, 2004-2008 (2008) Wkly. Epidemiol Rec 83: 145-154.
7. World Health organisation. (2004) Provisional guidance on the role of specific antibiotics in the managment of Mycobacterium ulcerans disease. Geneva.
8. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 3182-3186 doi:10.1128/AAC.49.8.3182-3186.2005.
9. Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, et al. (2010) Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis 4: e736 doi:10.1371/journal.pntd.0000736.
10. Chauty A, Ardant M-F, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob. Agents Chemother 51: 4029-4035.
11. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664-672 doi:10.1016/S0140-6736(09)61962-0.
12. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother 54: 3678-3685 doi:10.1128/AAC.00299-10.
13. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JAM, et al. (n.d.) All-Oral Antibiotic Treatment for Buruli Ulcer: A Report of Four Patients. PLoS Negl Trop Dis 4 doi:10.1371/journal.pntd.0000770.
14. Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. (2007) Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1: e2 doi:10.1371/journal.pntd.0000002.
15. O'Brien DP, Robson ME, Callan PP, McDonald AH, (2009) "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 191: 564-566.
16. Rondini S, Horsfield C, Mensah-Quainoo E, Junghanss T, Lucas S, et al. (2006) Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. The Journal of Pathology 208: 119-128.
17. Schütte D, UmBoock A, Pluschke G, (2009) Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. British Journal of Dermatology 160: 273-283.
18. WHO (2001) Buruli Ulcer. Diagnosis of Mycobacterium ulcerans disease (eds F Portaels, P Johnson, WM Meyers). WHO/CDS/CPE/GBUI/2001. 4.
19. Broughton G, Janis JE, Attinger CE, (2006) The basic science of wound healing. Plast Reconstr Surg 117: 12S-34S doi:10.1097/01.prs.0000225430.42531.c2.
20. Cornell RS, Meyr AJ, Steinberg JS, Attinger CE, (2010) Débridement of the noninfected wound. J Vasc Surg 52: 31S-36S doi:10.1016/j.jvs.2010.06.006.
21. Attinger CE, Janis JE, Steinberg J, Schwartz J, Al-Attar A, et al. (2006) Clinical approach to wounds: débridement and wound bed preparation including the use of dressings and wound-healing adjuvants. Plast Reconstr Surg 117: 72S-109S doi:10.1097/01.prs.0000225470.42514.8f.
22. Bowler PG, Duerden BI, Armstrong DG, (2001) Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 14: 244-269 doi:10.1128/CMR.14.2.244-269.2001.
23. Trengove NJ, Stacey MC, McGechie DF, Mata S, (1996) Qualitative bacteriology and leg ulcer healing. J Wound Care 5: 277-280.
24. Robson MC, Stenberg BD, Heggers JP, (1990) Wound healing alterations caused by infection. Clin Plast Surg 17: 485-492.